CANCER PATIENT EQUITY ACT
The major provisions of this Act include:
Molecular Diagnostics: Mandates coverage for molecular diagnostics at the time of diagnosis for patients on Medicare, Medicaid and CHIP.
Molecular diagnostics are a critical component of providing accurate diagnoses and enabling the use of next-generation targeted therapies. That information is especially important for cancers without modern standards of care, where clinical trials and targeted therapies may provide more hope for an improved outcome than typical chemotherapy and radiation regimens.
Education and Awareness: A program designed and implemented for physicians and the general public on what genomic testing is, how it can be used, and the role of genetic counselors.
Carried by the Secretary of Health and Human Services, in coordination with the Director of the National Human Genome Research Institute this program (through the inclusion of genomic education in graduate medical and continuing medical curriculums) will provide training on rare cancers and the importance of molecular diagnostics.
CLICK HERE TO CONTACT YOUR REPS AND SHOW YOUR SUPPORT FOR THE BILL
OFFICE OF CONGRESSMAN G. K. BUTTERFIELD
OFFICE OF CONGRESSMAN GUS BILIRAKIS